Gabather (GABA) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
6 Jun, 2025Guidance update and capital raise details
Gabather launches a rights issue of shares and warrants to raise SEK 21.4 million, with net proceeds of SEK 18.25 million after costs and loan repayment.
The rights issue consists of up to 23,773,496 units, each with 30 shares and 30 series TO 7 warrants, priced at SEK 0.90 per unit.
Subscription period is March 4–18, 2025, with trading in paid subscribed units (BTU) from March 4 to April 7, 2025.
The outcome will be published on March 20, 2025, and a prospectus is available on relevant websites.
Investor engagement and communication
Gabather invites stakeholders to web conferences on March 6 and 11, 2025, with CEO presentations and Q&A sessions.
Registration is required for the web conferences, with limited spots available.
Contact details for further information are provided, including CEO's phone and email.
Regulatory and legal considerations
The offering is only available in Sweden and not directed to jurisdictions where it would be illegal or require additional actions.
No securities will be registered under the US Securities Act or in other restricted jurisdictions; distribution is strictly limited.
In the UK, the offer is only available to qualified investors and certain professional or high net worth entities.
Gabather's business may be subject to Sweden's FDI law, requiring notification to authorities for certain foreign investments.
Latest events from Gabather
- Operating loss narrowed, but further financing is needed to sustain operations into 2026.GABA
Q4 202527 Feb 2026 - SEK 21.4 million rights issue supports Phase II GT-002 trial and March 2025 investor events.GABA
Investor Update27 Dec 2025 - Operating losses persist amid zero revenue and delayed clinical milestones; liquidity remains tight.GABA
Q3 202527 Nov 2025 - GT002 advances in phase 2 trials with patent progress and partnership talks targeting 2025 milestones.GABA
Investor Update24 Nov 2025 - GT002 enters phase II for schizophrenia cognition; TO 7 warrants could raise 5.3 MSEK.GABA
Investor Update20 Nov 2025 - Operating loss narrowed, but liquidity remains a concern as clinical progress continues.GABA
Q2 202528 Aug 2025 - Operating loss reduced, but negative equity and urgent financing needs persist.GABA
Q3 202413 Jun 2025 - Losses widened and liquidity remains strained as Gabather advances GT-002 clinical trials.GABA
Q2 202413 Jun 2025 - Operating loss reduced, liquidity boosted by rights issue, but funding risk persists.GABA
Q1 20256 Jun 2025